| Not Yet Recruiting | Screening for Brain Metastases NCT07492121 | University of Zurich | Phase 2 |
| Recruiting | Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanom NCT06319196 | University Health Network, Toronto | Phase 2 |
| Recruiting | To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma NCT06204991 | Inge Marie Svane | Phase 1 |
| Not Yet Recruiting | Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Pati NCT06780397 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma NCT06771544 | University of California, Irvine | Phase 2 |
| Recruiting | A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 | KaliVir Immunotherapeutics | Phase 1 |
| Recruiting | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in NCT06284590 | Philogen S.p.A. | Phase 2 |
| Recruiting | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma NCT06295159 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors NCT06425926 | Georgiamune Inc | Phase 1 / Phase 2 |
| Recruiting | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775 | Miltenyi Biomedicine GmbH | N/A |
| Recruiting | Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients NCT06199713 | University of Wisconsin, Madison | — |
| Unknown | Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet NCT06236360 | University Hospital Rijeka | N/A |
| Recruiting | A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497 | Krystal Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced NCT05655312 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial NCT05652673 | Erasmus Medical Center | N/A |
| Active Not Recruiting | Intrathecal Double Checkpoint Inhibition NCT05598853 | University of Zurich | Phase 1 |
| Unknown | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma NCT05370807 | Universitair Ziekenhuis Brussel | Phase 2 |
| Active Not Recruiting | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults Wi NCT05309421 | Evaxion Biotech A/S | Phase 2 |
| Recruiting | FMT to Convert Response to Immunotherapy NCT05251389 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy NCT05732805 | Biocad | Phase 3 |
| Completed | Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma NCT05303493 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Active Not Recruiting | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders NCT05286294 | Oslo University Hospital | Phase 2 |
| Recruiting | Versatile Ampification Single-Molecule Detection in Liquid Biopsy NCT05940311 | Regina Elena Cancer Institute | — |
| Recruiting | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastat NCT05296564 | Hadassah Medical Organization | Phase 1 / Phase 2 |
| Unknown | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice NCT05402059 | MelanomaPRO, Russia | — |
| Unknown | Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis NCT05070221 | Peking University Cancer Hospital & Institute | Phase 1 |
| Unknown | Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasi NCT05068453 | Peking University Cancer Hospital & Institute | Phase 1 |
| Unknown | pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and t NCT05171374 | MelanomaPRO, Russia | — |
| Recruiting | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma NCT04741997 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients Wi NCT04526899 | BioNTech SE | Phase 2 |
| Unknown | Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients NCT06556004 | University of Chile | Phase 1 |
| Withdrawn | Surgery of Melanoma Metastases After Systemic Therapy NCT04242329 | Vastra Gotaland Region | Phase 2 |
| Completed | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy NCT04904120 | Perspective Therapeutics | Phase 1 |
| Recruiting | Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma NCT04598009 | University of California, San Francisco | Phase 2 |
| Unknown | Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells NCT04628806 | Charite University, Berlin, Germany | — |
| Recruiting | Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma NCT04513028 | Kelly McMasters | N/A |
| Unknown | A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inope NCT04521075 | Ella Therapeutics Ltd | Phase 1 / Phase 2 |
| Recruiting | IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients NCT04562129 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Mel NCT04330430 | The Netherlands Cancer Institute | Phase 2 |
| Active Not Recruiting | Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis NCT04305145 | Massachusetts General Hospital | Phase 2 |
| Terminated | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Co NCT04410445 | Nektar Therapeutics | Phase 3 |
| Terminated | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 NCT04455503 | Evaxion Biotech A/S | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors NCT04478279 | Sapience Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD NCT04139902 | Diwakar Davar | Phase 2 |
| Completed | Appropriate Dosing to Optimise Personalised Cancer Treatments NCT04154163 | University of Dundee | — |
| Active Not Recruiting | Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immuno NCT04990726 | M.D. Anderson Cancer Center | — |
| Recruiting | Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment NCT04045691 | Pierre Fabre Pharma GmbH | — |
| Withdrawn | A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS NCT04007588 | Dana-Farber Cancer Institute | Phase 2 |
| Active Not Recruiting | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SC NCT04079166 | Scancell Ltd | Phase 2 |
| Recruiting | Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) NCT03340129 | Melanoma Institute Australia | Phase 2 |
| Active Not Recruiting | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab NCT03161431 | Syntrix Biosystems, Inc. | Phase 1 |
| Terminated | High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal NCT03991130 | Gregory Daniels | Phase 2 |
| Completed | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma NCT03620019 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain NCT03605771 | Grupo Español Multidisciplinar de Melanoma | — |
| Unknown | Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Meta NCT03161756 | Melanoma and Skin Cancer Trials Limited | Phase 1 / Phase 2 |
| Unknown | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy NCT03353402 | Sheba Medical Center | Phase 1 |
| Completed | A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic NCT03153085 | Takara Bio Inc. | Phase 2 |
| Unknown | Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastati NCT03190824 | Syneos Health | Phase 2 |
| Completed | Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study NCT03879395 | Vastra Gotaland Region | — |